Cancer Risk With Advanced Therapies in Patients With Inflammatory Bowel Diseases: An Administrative Claims–Based Study
Clinical Gastroenterology and Hepatology · 2026-08
DOI: 10.1016/j.cgh.2026.08.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-08. Verfasst von Dhruv Ahuja und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Indira Gandhi Hospital, New Delhi, India. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NIDDK NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
BACKGROUND & AIMS: We conducted a retrospective cohort study comparing the risk of cancer in patients with inflammatory bowel diseases (IBDs) initiating advanced therapies (ATs). METHODS: Using an administrative claims database (OptumLabs Data Warehouse), we identified patients with IBD with no prior history of cancer, who initiated tumor necrosis factor (TNF) antagonists, vedolizumab, anti-interleukins (ILs), or Janus kinase (JAK) inhibitors between 2016 and 2023 and had insurance coverage for at least 1 year before and after treatment initiation. We compared risk of overall cancer (except nonmelanoma skin cancer) across different ATs occurring at least 3 months after treatment initiation. Groups were balanced through multinomial propensity score-based inverse probability weighting. We calculated cause-specific hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: Of 15,687 patients with IBD starting an AT (age, 45 ± 17 years; 52% female; 76% White; 14% with obesity) and followed over a median of 2.6 years, 273 developed cancer. The 3-year cumulative incidence of cancer was similar across all agents: TNF antagonists (n = 8031), 2.1% (95% CI, 1.7-2.5); vedolizumab (n = 3985), 2.7% (95% CI, 2.1-3.3); anti-ILs (n = 3287), 2.0% (95% CI, 1.4-2.6); and JAK inhibitors (n = 384), 2.5% (95% CI, 0.5-4.6). After adjusting for confounding variables, risk of cancer with ATs was comparable (HR, vs TNF antagonists): vedolizumab, 1.01 (95% CI, 0.71-1.42); anti-ILs, 0.94 (95% CI, 0.61-1.46); JAK inhibitors, 0.85 (95% CI, 0.33-2.16). The findings were similar on subgroup analyses based on type of cancer (solid organ, hematologic, melanoma), and on multiple sensitivity analyses. Findings were consistent in agent-level analyses and in an indirect comparison with a cohort of immunomodulator- and advanced therapy-naïve patients with newly diagnosed IBD. CONCLUSIONS: In a real-world cohort of 15,687 patients with IBD initiating ATs, risk of incident cancer was low and comparable across advanced therapy classes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Indira Gandhi Hospital, New Delhi, India.
- Division of Biomedical Informatics, Department of Medicine, University of California San Diego, La Jolla, California.
- Department of Gastroenterology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.
- Biostatistics and Bioinformatics, Herbert Wertheim School of Public Health, University of California San Diego, La Jolla, California.
- Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California.
- Division of Gastroenterology, Western University, London, Ontario, Canada.
Förderung
- NIAMS NIH HHS
- NIDDK NIH HHS
- NIA NIH HHS
- National Institute of Arthritis Diabetes and Digestive and Kidney Diseases
- Crohn's and Colitis Foundation of America
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Institute on Aging
Zitieren
APA
Ahuja, D., Yeh, K. H., Park, S. K., Qi, Y., Patel, S. B., Goodwin, S. W., Vuyyuru, S. K., Malik, T. A., Ramos, G. P., Silverman, A., Singh, N., Olen, O., Ananthakrishnan, A. N., Jairath, V., Xu, R., & Singh, S. (2026). Cancer Risk With Advanced Therapies in Patients With Inflammatory Bowel Diseases: An Administrative Claims–Based Study. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.08.003
Vancouver
Ahuja D, Yeh KH, Park SK, Qi Y, Patel SB, Goodwin SW, et al. Cancer Risk With Advanced Therapies in Patients With Inflammatory Bowel Diseases: An Administrative Claims–Based Study. Clinical Gastroenterology and Hepatology. 2026. doi:10.1016/j.cgh.2026.08.003
BibTeX
@article{Ahuja2026,
author = {Ahuja, Dhruv and Yeh, Kuan-Hung and Park, Soo-Kyung and Qi, Yuchen and Patel, Sagar B and Goodwin, Shane W and Vuyyuru, Sudheer K and Malik, Talha A and Ramos, Guilherme Piovezani and Silverman, Anna and Singh, Namrata and Olen, Ola and Ananthakrishnan, Ashwin N and Jairath, Vipul and Xu, Ronghui and Singh, Siddharth},
title = {Cancer Risk With Advanced Therapies in Patients With Inflammatory Bowel Diseases: An Administrative Claims–Based Study},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
doi = {10.1016/j.cgh.2026.08.003}
}
EUVIMED